Clal Biotechnology Industries has announced that Sight Diagnostics, in which it holds a 3.5% stake through Anatomy, its fund for investment in medical devices, has completed a successful clinical trial for its device.
Read more here.
Clal Biotechnology Industries has announced that Sight Diagnostics, in which it holds a 3.5% stake through Anatomy, its fund for investment in medical devices, has completed a successful clinical trial for its device.
Read more here.
![[Trusona in Digital Trends] How 20th century check fraud is helping prevent 21st century data theft](https://blog.gold.ocdvlp.com/wp-content/themes/Extra/images/post-format-thumb-text.svg)
